After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Tectonic Therapeutic (TECX) plunges as Eli Lilly (LLY) ends a mid-stage trial for its kidney drug volenrelaxin which is similar to TECX's lead drug TX45. Read more here.

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3% ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...